{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:28:38Z","timestamp":1750793318025,"version":"3.40.3"},"reference-count":20,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100009053","name":"Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/CPHI\/18\/1\/503975"],"award-info":[{"award-number":["IA\/CPHI\/18\/1\/503975"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2024,6,30]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tuberculosis (TB)-immunoreactivity, measured in vivo (tuberculin skin test (TST)) or in vitro (interferon gamma release assay (IGRA)), can be found in latent, active or even following clearance of TB infection. In this case-control study, we compared the systemic and ocular outcomes between patients with or without TB-immunoreactivity, who received immunomodulatory therapy (IMT) for non-infectious uveitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed charts of patients with (cases) or without (controls) TB-immunoreactivity (TST\u00b1IGRA), who received conventional IMT for \u22656 months, for the treatment of non-infectious uveitis. Patients who received prior or concomitant anti-TB therapy were excluded. Systemic and ocular outcomes were compared between both groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>36 cases and 70 controls (gender-matched and age-matched) were included. New-onset pulmonary or extrapulmonary TB developed in one case and none of the controls. Based on this outcome, the absolute risk increase for systemic TB reactivation was noted to be 0.028 (95% CI 0.005 to 0.051) and the number needed to harm was 36. The incidence of persistent or recurrent (worsening \u22652 grades) intraocular inflammation during IMT was comparable between both groups (cases 18\/36, controls 35\/70, p=1.0). A change in anatomical site of presentation at recurrence was not seen in any case, but in six controls (p=0.15). No new focal chorio-retinal lesions were noted in either group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Conventional IMT has a very low risk of systemic TB reactivation, and no additional detrimental effect on ocular outcomes, in TB-immunoreactive patients with non-infectious uveitis.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjo-2024-325625","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T17:20:36Z","timestamp":1721064036000},"page":"41-44","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic and ocular outcomes in TB-immunoreactive patients receiving immunomodulatory therapy for non-infectious uveitis: a case-control study"],"prefix":"10.1136","volume":"109","author":[{"given":"Shravya","family":"Choudhary Balla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Hasnat","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudit","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6513-8786","authenticated-orcid":false,"given":"Soumyava","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"2025040105500996000_109.1.41.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k2738","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"},{"key":"2025040105500996000_109.1.41.2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/09273948.2016.1245760","article-title":"Looking for ocular tuberculosis: prevalence and clinical manifestations of patients with uveitis and positive QuantiFERON\u00ae-TB gold test","volume":"26","author":"Pathanapitoon","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2025040105500996000_109.1.41.3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/eye.2017.231","article-title":"Tuberculosis and other causes of uveitis in Indonesia","volume":"32","author":"La Distia Nora","year":"2018","journal-title":"Eye"},{"key":"2025040105500996000_109.1.41.4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajo.2019.11.009","article-title":"Prevalence of positive QuantiFERON-TB gold in-tube test in uveitis and its clinical implications in a country nonendemic for tuberculosis","volume":"211","author":"Groen-Hakan","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"2025040105500996000_109.1.41.5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2021.04.024","article-title":"The association between QuantiFERON-TB gold test and clinical manifestations of uveitis in the United States","volume":"230","author":"Yakin","year":"2021","journal-title":"Am J Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.6","DOI":"10.1136\/ard-2022-223335"},{"key":"2025040105500996000_109.1.41.7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajo.2021.03.040","article-title":"Classification criteria for tubercular uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"2025040105500996000_109.1.41.8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ophtha.2020.01.008","article-title":"Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 1: guidelines for initiating antitubercular therapy in tubercular choroiditis","volume":"128","author":"Agrawal","year":"2021","journal-title":"Ophthalmology"},{"key":"2025040105500996000_109.1.41.9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ophtha.2020.06.052","article-title":"Collaborative ocular tuberculosis study consensus guidelines on the management of tubercular uveitis-report 2: guidelines for initiating antitubercular therapy in anterior uveitis, intermediate uveitis, panuveitis, and retinal vasculitis","volume":"128","author":"Agrawal","year":"2021","journal-title":"Ophthalmology"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.10","DOI":"10.1056\/NEJMra1405427"},{"key":"2025040105500996000_109.1.41.11","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2011-301416","article-title":"Anti-tubercular treatment is not required in latent tuberculosis","volume":"96","author":"Nazari","year":"2012","journal-title":"Br J Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.12","DOI":"10.1002\/art.24476"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.13","DOI":"10.1086\/506935"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.14","DOI":"10.1136\/thoraxjnl-2014-206470"},{"key":"2025040105500996000_109.1.41.15","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.4103\/ijo.IJO_362_20","article-title":"Tubercular subretinal abscess in a pediatric intermediate uveitis patient on methotrexate","volume":"68","author":"Nair","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"2025040105500996000_109.1.41.16","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","article-title":"Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatol"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.17","DOI":"10.1016\/S0140-6736(15)01316-1"},{"key":"2025040105500996000_109.1.41.18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2022.08.029","article-title":"Antigen-specific intraocular cytokine responses distinguish ocular tuberculosis from undifferentiated uveitis in tuberculosis-immunoreactive patients","volume":"246","author":"Alam","year":"2023","journal-title":"Am J Ophthalmol"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.19","DOI":"10.4049\/jimmunol.1101122"},{"doi-asserted-by":"publisher","key":"2025040105500996000_109.1.41.20","DOI":"10.4049\/jimmunol.1900230"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-325625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:01:00Z","timestamp":1743541260000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-325625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bjo-2024-325625"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-325625","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}